Free Trial

Pliant Therapeutics (PLRX) News Today

→ Protect Your Bank Account Before It’s Too Late (From Weiss Ratings) (Ad)
Free PLRX Stock Alerts
$11.15
-0.39 (-3.38%)
(As of 06/7/2024 ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends
June 9 at 2:24 AM | americanbankingnews.com
Analysts Set Pliant Therapeutics, Inc. (NASDAQ:PLRX) Target Price at $45.38
June 9 at 1:44 AM | americanbankingnews.com
Pliant Therapeutics (NASDAQ:PLRX) Sets New 1-Year Low at $11.21
June 8 at 5:21 AM | americanbankingnews.com
Pliant Therapeutics (NASDAQ:PLRX) Given "Buy" Rating at HC Wainwright
June 7 at 10:41 AM | marketbeat.com
Pliant Therapeutics (NASDAQ:PLRX) Reaches New 52-Week Low at $11.21
Pliant Therapeutics (NASDAQ:PLRX) Sets New 1-Year Low at $11.21
June 7 at 8:10 AM | marketbeat.com
HC Wainwright Reiterates "Buy" Rating for Pliant Therapeutics (NASDAQ:PLRX)
HC Wainwright reissued a "buy" rating and issued a $36.00 target price on shares of Pliant Therapeutics in a report on Friday.
June 7 at 4:17 AM | marketbeat.com
UBS Group AG Purchases 71,369 Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX)
UBS Group AG boosted its position in Pliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) by 26.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 342,173 shares of the company's stock after purchasing an
June 6 at 8:00 AM | globenewswire.com
Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™
June 6 at 7:50 AM | americanbankingnews.com
Pliant Therapeutics (NASDAQ:PLRX) Sees Unusually-High Trading Volume
June 6 at 1:37 AM | marketbeat.com
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Average Recommendation of "Buy" by Brokerages
Pliant Therapeutics, Inc. (NASDAQ:PLRX - Get Free Report) has been given an average rating of "Buy" by the nine research firms that are covering the company, Marketbeat.com reports. Nine equities research analysts have rated the stock with a buy recommendation. The average 12-month target price am
June 4, 2024 | marketbeat.com
Rhenman & Partners Asset Management AB Sells 217,894 Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX)
Rhenman & Partners Asset Management AB cut its holdings in Pliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) by 65.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 112,741 shares of the company'
June 4, 2024 | marketbeat.com
Pliant Therapeutics (NASDAQ:PLRX) Sees Strong Trading Volume
Pliant Therapeutics (NASDAQ:PLRX) Sees Strong Trading Volume
May 27, 2024 | marketbeat.com
Franklin Resources Inc. Acquires 62,173 Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX)
Franklin Resources Inc. boosted its holdings in shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) by 4.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,579,572 shares of the company's stock after purchasing an
May 24, 2024 | marketbeat.com
Pliant Therapeutics (NASDAQ:PLRX) Stock Price Down 4.5%
Pliant Therapeutics (NASDAQ:PLRX) Stock Price Down 4.5%
May 21, 2024 | globenewswire.com
Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference
May 16, 2024 | markets.businessinsider.com
Buy Rating Affirmed for Pliant Therapeutics on Promising Bexotegrast Trial Results in IPF
May 15, 2024 | markets.businessinsider.com
Analysts Are Bullish on These Healthcare Stocks: Pliant Therapeutics (PLRX), Trevena (TRVN)
May 15, 2024 | marketbeat.com
Pliant Therapeutics (NASDAQ:PLRX) Trading Up 5.5%
Pliant Therapeutics (NASDAQ:PLRX) Shares Up 5.5%
May 15, 2024 | marketbeat.com
HC Wainwright Reaffirms Buy Rating for Pliant Therapeutics (NASDAQ:PLRX)
HC Wainwright reissued a "buy" rating and issued a $36.00 price target on shares of Pliant Therapeutics in a research note on Wednesday.
May 15, 2024 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Pliant Therapeutics (PLRX) and Tenet Healthcare (THC)
May 14, 2024 | marketbeat.com
Pliant Therapeutics (NASDAQ:PLRX) Shares Gap Up to $13.67
Pliant Therapeutics (NASDAQ:PLRX) Shares Gap Up to $13.67
May 14, 2024 | msn.com
Pliant Therapeutics' Drug Trial Shows Promise In Reversing Lung Fibrosis In Patients
May 14, 2024 | globenewswire.com
Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis
May 10, 2024 | marketbeat.com
HC Wainwright Comments on Pliant Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:PLRX)
Pliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) - HC Wainwright decreased their Q2 2024 earnings per share estimates for Pliant Therapeutics in a report released on Tuesday, May 7th. HC Wainwright analyst E. Arce now expects that the company will post earnings of ($0.82) per share for the q
May 8, 2024 | markets.businessinsider.com
Pliant Therapeutics: Advancing Trials and Diversifying Pipeline Justify Buy Rating
May 8, 2024 | markets.businessinsider.com
Buy Rating for Pliant Therapeutics: Promising Trials and Strategic Shifts Signal Growth Potential
May 8, 2024 | finance.yahoo.com
Pliant Therapeutics First Quarter 2024 Earnings: US$0.78 loss per share (vs US$0.67 loss in 1Q 2023)
May 7, 2024 | markets.businessinsider.com
Bullish Outlook: Buy Rating on Pliant Therapeutics Amid Strong Clinical Trials and Solid Financials
May 7, 2024 | markets.businessinsider.com
Buy Rating Justified by Pliant Therapeutics’ Promising Pipeline and Financial Prudence
May 7, 2024 | msn.com
These Analysts Revise Their Forecasts On Pliant Therapeutics Following Q1 Earnings
May 7, 2024 | marketbeat.com
Citigroup Trims Pliant Therapeutics (NASDAQ:PLRX) Target Price to $44.00
Citigroup cut their price objective on Pliant Therapeutics from $45.00 to $44.00 and set a "buy" rating on the stock in a research report on Tuesday.
May 7, 2024 | tmcnet.com
Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™
May 7, 2024 | finance.yahoo.com
Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™
May 7, 2024 | marketbeat.com
Pliant Therapeutics (NASDAQ:PLRX) PT Raised to $48.00 at Oppenheimer
Oppenheimer raised their price target on shares of Pliant Therapeutics from $47.00 to $48.00 and gave the company an "outperform" rating in a report on Tuesday.
May 7, 2024 | marketbeat.com
Pliant Therapeutics' (PLRX) Buy Rating Reiterated at HC Wainwright
HC Wainwright reaffirmed a "buy" rating and issued a $36.00 price objective on shares of Pliant Therapeutics in a research report on Tuesday.
May 6, 2024 | investorplace.com
PLRX Stock Earnings: Pliant Therapeutics Misses EPS for Q1 2024
May 6, 2024 | globenewswire.com
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
May 1, 2024 | marketbeat.com
Pliant Therapeutics (NASDAQ:PLRX) Sees Large Volume Increase
Pliant Therapeutics (NASDAQ:PLRX) Sees Strong Trading Volume
May 1, 2024 | globenewswire.com
Pliant Therapeutics to Participate in Upcoming Investor Events
April 24, 2024 | marketbeat.com
Pliant Therapeutics (NASDAQ:PLRX) Hits New 1-Year Low at $11.91
Pliant Therapeutics (NASDAQ:PLRX) Reaches New 1-Year Low at $11.91
April 10, 2024 | marketbeat.com
Pliant Therapeutics (NASDAQ:PLRX) Stock Rating Reaffirmed by Needham & Company LLC
Needham & Company LLC reaffirmed a "buy" rating and set a $38.00 target price on shares of Pliant Therapeutics in a research note on Wednesday.
April 9, 2024 | investing.com
Pliant Therapeutics Inc (PLRX)
April 9, 2024 | marketbeat.com
Vanguard Group Inc. Purchases 168,454 Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX)
Vanguard Group Inc. boosted its position in Pliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) by 6.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,945,312 shares of the company's stock after acquir
April 2, 2024 | globenewswire.com
Pliant Therapeutics to Participate in Upcoming Investor Events
March 27, 2024 | globenewswire.com
Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference
March 20, 2024 | marketbeat.com
Deutsche Bank AG Has $17.09 Million Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX)
Deutsche Bank AG lessened its holdings in Pliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) by 23.6% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 985,569 shares of the company's stock after selling 305,083 share
March 17, 2024 | finance.yahoo.com
PLRX Oct 2024 30.000 call
March 16, 2024 | finance.yahoo.com
PLRX Oct 2024 7.500 put
March 12, 2024 | finanznachrichten.de
Pliant Therapeutics, Inc.: Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis
March 12, 2024 | globenewswire.com
Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis
March 11, 2024 | marketbeat.com
Pliant Therapeutics (NASDAQ:PLRX) Trading Down 6.2%
Pliant Therapeutics (NASDAQ:PLRX) Shares Down 6.2%
Get Pliant Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PLRX and its competitors with MarketBeat's FREE daily newsletter.

Protect Your Bank Account Before It’s Too Late (Ad)

For months I’ve been warning about the federal government’s terrifying new program to control every American’s bank account. It gives them the power to monitor every single transaction …

Stop right now and do these 3 things to protect yourself

PLRX Media Mentions By Week

PLRX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

PLRX
News Sentiment
▼
0.46

0.76
▲
Average
Medical
News Sentiment

PLRX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

PLRX Articles
This Week
▼
12

2
▲
PLRX Articles
Average Week

Get Pliant Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PLRX and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NASDAQ:PLRX) was last updated on 6/9/2024 by MarketBeat.com Staff

From Our Partners
Collapse of the Petrodollar
The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...
Colonial Metals | Sponsored
Top 5 Tech Stocks to Buy for 2024
The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...
Daily Market Alerts | Sponsored
Top 5 AI Stocks to Buy for 2024
The electric vehicle boom is accelerating – and fast.
Market Moving Trends | Sponsored
No Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for Free
Optimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...
Hedgeye | Sponsored
AI's Next Magnificent Seven
The Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.
The Oxford Club | Sponsored
Major Elon Musk Crypto Leak Revealed
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...
Crypto 101 Media | Sponsored
The Only Energy Play You Should Be Looking At
Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...
Wealthpin Pro | Sponsored
Exposed: 3 CENT Crypto to Explode June 24th?
Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...
True Market Insiders | Sponsored